IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer

IDEAYA Biosciences, Inc.

Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.
Merck provides KEYTRUDA at no cost; IDEAYA sponsors the trial and pays study costs.
Each party retains full commercial rights to its own compound as monotherapy or combination.
IDE161 has FDA Fast-Track designation for BRCA1/2 ovarian and breast cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.